D-Limonene, a common monoterepene has been shown to have antiproliferative, apoptosis-inducing and chemopreventive effects. In the present study, we have investigated the effects of
D-limonene on the growth of 7,12-dimethylbenz[a]
anthracene (DMBA)-initiated and 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted skin
tumor development. We found that
D-limonene (50 and 100 mg/kg
body weight) treatments to the mouse skin significantly reduced the TPA-induced (a)
edema and
hyperplasia (p < 0.001); (b) expression of
cyclooxygenase-2; (c)
ornithine decarboxylase activity (p < 0.001); and (d) [(3)H]
thymidine incorporation into
DNA (p < 0.001). In addition, treatment of
D-limonene effectively restored the level of
reduced glutathione,
glutathione peroxidase,
glutathione reductase,
glutathione S-transferase,
catalase and
malondialdehyde production in TPA-treated mouse skin. In a two-stage skin
tumorigenesis study,
D-limonene significantly reduced the
tumor burden (p < 0.005) and
tumor incidence as compared to DMBA/TPA-treated mice.
D-Limonene treatment also extended the latency period of
tumor development from 4 to 9 weeks.
D-Limonene treatment decreased the expression level of Ras, Raf and phosphorylation of extracellular signal-regulated
protein kinase 1/2 in DMBA/TPA-induced
tumors. A decrease in the expression of Bcl-2 and an increase in Bax expression were also observed in
tumor tissues of mice treated with
D-limonene. Taken together, our findings suggest that
D-limonene may exert its chemopreventive activity through the inhibition of
inflammation, oxidative stress and Ras-signaling as well as the induction of pro-apoptotic state during TPA-mediated promotion of DMBA-induced
skin cancer in mouse model.